Myeloid Derived Suppressor Cells Control by Signal Regulatory Protein-alpha: Investigation in Hepatocellular Carcinoma

Study Overview
=================
Brief Summary
-----------------
project is to study and develop anti-Signal Regulatory Protein α (SIRPα) antibodies (Ab) as a new immunotherapy strategy in cancer. Samples harvested from hepatocellular carcinoma (HCC) and ovarian cancer patients will be used in evaluation of the SIRP-CD47 expression and of the effect of the anti-human Signal Regulatory Protein (hSIRP) Ab on various cellular types from patients and healthy volunteers.

Official Title
-----------------
Myeloid Derived Suppressor Cells Control by SIRP-alpha: Investigation in Hepatocellular Carcinoma

Conditions
-----------------
Hepatocellular Carcinoma

Intervention / Treatment
-----------------
* Procedure: Collection of human samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult HCC patients (all BCLC stages accepted) patient consent for the use of their biological samples Exclusion Criteria: patient with other cancers hepatitis C or B positive HCC treatment by chemo-embolization under 3 months under Sorafenib treatment within the month prior to collection underage or under guardianship patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ascites<br>30 inflammatory ascites of HCC patients (Collection of human samples ) Ascites will be selected only from HCC patients with an elevated protein level (ie inflammatory ascites) Puncture of ascites will be collected by paracentesis on HCC or ovarian cancer patients during their routine care These biological samples are affiliated with the biobank hépato-gastroentérologie du CHU de Nantes (declared under the reference DC-2011-1399). | Procedure: Collection of human samples<br>* Several types of samples will be used to test the effect of the drug candidate<br>|
| Resections<br>30 HCC resections (Collection of human samples ) Fragment of resected HCC will be obtained after surgery and histological analysis will be performed by the anatomo-pathology service These biological samples are affiliated with the biobank hépato-gastroentérologie du CHU de Nantes (declared under the reference DC-2011-1399). | Procedure: Collection of human samples<br>* Several types of samples will be used to test the effect of the drug candidate<br>|
| blood samples<br>blood samples (Collection of human samples )will be collected prospectively for complementary functional analysis of peripheral These biological samples are affiliated with the biocollection hépato-gastroentérologie du CHU de Nantes (declared under the reference DC-2011-1399). | Procedure: Collection of human samples<br>* Several types of samples will be used to test the effect of the drug candidate<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| evaluation of the SIRP/CD47 expression | samples harvested from HCC and ovarian cancer patients will be used in evaluation of the SIRP-CD47 expression and of the effect of the anti-hSIRP Ab on various cellular types from patients | baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Biobank analyses, Effect evaluation of the drug, patient-derived cells, SIRPα/CD47 expression